Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -213.77% is 213% below its 5-year average of -68.22%, near the low end of its 5-year range (-213.77%–-17.79%).
93.45% below its 12-month average of -110.51%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -68.06%.
RETURN ON ASSETS (ROA)
-213.77%
RETURN ON ASSETS (ROA) AVG TTM
-110.51%
RETURN ON ASSETS (ROA) AVG 3Y
-93.41%
RETURN ON ASSETS (ROA) AVG 5Y
-68.22%
RETURN ON ASSETS (ROA) AVG 10Y
-66.59%
RETURN ON ASSETS (ROA) AVG 15Y
-64.61%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-93.45%
CURRENT VS 3Y AVG
-128.85%
CURRENT VS 5Y AVG
-213.37%
CURRENT VS 10Y AVG
-221.03%
CURRENT VS 15Y AVG
-230.89%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-563.06%
vs the sector median at left
Cocrystal Pharma, Inc.
Market Cap
$15.24M
Return on Assets (ROA)
-213.77%
TTM Avg
-110.51%
3Y Avg
-93.41%
5Y Avg
-68.22%
Market Cap
$14.89M
Return on Assets (ROA)
-41.18%
TTM Avg
-60.23%
3Y Avg
-53.11%
5Y Avg
-40.22%
Market Cap
$15.03M
Return on Assets (ROA)
2.23%
TTM Avg
5.13%
3Y Avg
7.99%
5Y Avg
9.09%
Market Cap
$15.40M
Return on Assets (ROA)
-201.89%
TTM Avg
-113.65%
3Y Avg
-83.24%
5Y Avg
-72.72%
Market Cap
$15.65M
Return on Assets (ROA)
-38.41%
TTM Avg
-84.87%
3Y Avg
-95.12%
5Y Avg
-75.66%
Market Cap
$15.93M
Return on Assets (ROA)
-154.34%
TTM Avg
-227.23%
3Y Avg
-240.86%
5Y Avg
-184.63%
Market Cap
$14.24M
Return on Assets (ROA)
-15.57%
TTM Avg
-20.73%
3Y Avg
-20.84%
5Y Avg
-41.87%
Market Cap
$14.11M
Return on Assets (ROA)
-123.23%
TTM Avg
-153.35%
3Y Avg
-205.77%
5Y Avg
-166.29%
Market Cap
$16.40M
Return on Assets (ROA)
-116.60%
TTM Avg
-66.28%
3Y Avg
-71.56%
5Y Avg
-63.10%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | $15.24M | -213.77% | -110.51% | -93.41% | -68.22% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.89M | -41.18% | -60.23% | -53.11% | -40.22% |
| Jin Medical International Ltd. (ZJYL)vs › | $15.03M | 2.23% | 5.13% | 7.99% | 9.09% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.40M | -201.89% | -113.65% | -83.24% | -72.72% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.65M | -38.41% | -84.87% | -95.12% | -75.66% |
| BioCardia, Inc. (BCDA)vs › | $15.93M | -154.34% | -227.23% | -240.86% | -184.63% |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.24M | -15.57% | -20.73% | -20.84% | -41.87% |
| Vyome Holdings, Inc. (HIND)vs › | $14.11M | -123.23% | -153.35% | -205.77% | -166.29% |
| Dyadic International, Inc. (DYAI)vs › | $16.40M | -116.60% | -66.28% | -71.56% | -63.10% |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.03M | N/A | N/A | N/A | N/A |
ROA
-213.8%
ROE
-951.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -90.93% |
| 2024-12-31 | -130.08% |
| 2023-12-31 | -57.53% |
| 2022-12-31 | -95.10% |
| 2021-12-31 | -17.87% |
| 2020-12-31 | -17.79% |
| 2019-12-31 | -168.83% |
| 2018-12-31 | -71.54% |
| 2017-12-31 | -0.50% |
| 2016-12-31 | -59.96% |
| 2015-12-31 | -22.35% |
| 2014-12-31 | -0.04% |
| 2013-12-31 | -303.92% |
| 2012-12-31 | -110.01% |
| 2011-12-31 | -72.31% |
| 2010-12-31 | -54.24% |
| 2009-12-31 | -36.76% |
| 2008-12-31 | -38.57% |
| 2007-12-31 | -34.30% |
